The primary efficacy end point was the percent change
in LDL-C from baseline to week 24, analyzed using an
intention-to-treat (ITT) approach. Key secondary efficacy
end points included percent change in LDL-C from
baseline to week 24 (on-treatment analysis), percent
change in LDL-C at other defined time points, percent
changes in other lipid parameters, and proportion of
patients reaching LDL-C b70 mg/dL.1